191092-05-4

Basic information

• Product Name: tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate
• Synonyms: tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate;1-Boc-3-(tosyloxymethyl)piperidine
• CAS NO: 191092-05-4
• Molecular Formula: C₁₈H₂₇NO₅S
• Molecular Weight: 369.47568
• Mol File: 191092-05-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate(191092-05-4)
• EPA Substance Registry System: tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate(191092-05-4)

Safety Data

• Hazardous Substances Data: 191092-05-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate is a chemical compound with a complex structure. It consists of a piperidine ring with a tert-butyl ester and a p-tolylsulfonyloxymethyl group attached to it. The p-tolylsulfonyloxymethyl group is a protecting group commonly used in organic synthesis to protect alcohols or amines from unwanted reactions. tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate may have applications in organic synthesis and pharmaceutical research as a building block or a precursor for the synthesis of more complex molecules. Overall, it is a versatile and potentially useful compound in various chemical and pharmaceutical applications.

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 116574-71-1 (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 167143-51-3 1-tert-butoxycarbonyl-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxymethyl]piperidine 
• 957621-65-7 toluene-4-sulfonic acid piperidin-3-ylmethyl ester, hydrochloride 
• 162167-97-7 tert-butyl 3-(aminomethyl)piperidine-1-carboxylate 
• 948015-72-3 tert-butyl 3-(cyanomethyl)piperidine-1-carboxylate 
• 1026901-58-5 1-acetyl-3-{2-[4-(3-methoxyphenyl)butyl]phenoxymethyl}piperidine 

Relevant articles and documents

Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities

Accumulation of cytotoxic lipofuscin bisretinoids may contribute to atrophic age-related macular degeneration (AMD) pathogenesis. Retinal bisretinoid synthesis depends on the influx of serum all-trans-retinol (1) delivered via a tertiary retinol binding protein 4 (RBP4)-transthyretin (TTR)-retinol complex. We previously identified selective RBP4 antagonists that dissociate circulating RBP4-TTR-retinol complexes, reduce serum RBP4 levels, and inhibit bisretinoid synthesis in models of enhanced retinal lipofuscinogenesis. However, the release of TTR by selective RBP4 antagonists may be associated with TTR tetramer destabilization and, potentially, TTR amyloid formation. We describe herein the identification of bispecific RBP4 antagonist-TTR tetramer kinetic stabilizers. Standout analogue (±)-44 possesses suitable potency for both targets, significantly lowers mouse plasma RBP4 levels, and prevents TTR aggregation in a gel-based assay. This new class of bispecific compounds may be especially important as a therapy for dry AMD patients who have another common age-related comorbidity, senile systemic amyloidosis, a nongenetic disease associated with wild-type TTR misfolding.

INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF

The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

IH-indol-5-YL-piperazin-1-YL-methanone derivatives

The present invention relates to compounds of formula I and their pharmaceutically acceptable salts wherein in formula I is: wherein R1 to R4 are as defined in the description and claims. The compounds of the present invention are us